**Name of the journal: World Journal of Cardiology**

**ESPS Manuscript NO: 14740**

**Columns: ORIGINAL ARTICLE**

***Prospective Study***

**Effective treatment of depression improves post-myocardial infarction survival**

Banankhah SK *et al*. Effective post-MI depression treatment and survival

Soudabeh Khojasteh Banakhah, Erika Friedmann, Sue Thomas

**Soudabeh Khojasteh Banankhah**, **Erika Friedmann**, **Sue Thomas**, School of Nursing, University of Maryland, Baltimore, MD 21201, United States

**Author contributions**: Banankhah SK contributed to the conception of the study; Banankhah SK and Thomas S designed; Friedmann E acquisition of data; Banankhah SK and Friedmann E analyzed and interpreted the data; Banankhah SK wrote the paper; and Banankhah SK, Friedmann E and Thomas S revised the manuscript for final submission.

**Ethics approval:** The study was reviewed and approved by the University of Maryland Institutional Review Board.

**Clinical trial registration:** This study is registered at http://clinicaltrial.gov/ct2/show/NCT00000557?term=ENRICHD&rank=1, The clinical Trials.gov Identifier: NCT00000557

**Informed consent:** This study is a secondary data analysis using data from the ENRICHD randomized trial and received in a de-identified format.

**Conflict-of-interest:** The authors have no relationships with industry to report and have no conflict of interest including financial, personal, political interest in this study.

**Data sharing:** Technical appendix and statistical code are available from the corresponding author at sbana001@umaryland.edu. The ENRICHD limited use data set is available from NIH by application through BIOLINCC at https://biolincc.nhlbi.nih.gov/home/

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

**Correspondence to: Soudabeh Khojasteh Banankhah, CRNP, CRNA, PhD,** School of Nursing, University of Maryland, 655 W. Lombard St., Room 316, Baltimore, MD 21201, United States. sbanank1@jhmi.edu

**Telephone:** +1-443-2804901

**Received:** October 22, 2014

**Peer-review started:** October 22, 2014

**First decision:** November 27, 2014

**Revised:** January 7, 2015

**Accepted:** February 4, 2015

**Article in press:**

**Published online:**

**Abstract**

**AIM:** To examine the contribution of treatment resistant depression (TRD) to mortality in depressed post-myocardial infarction (MI) patients independent of biological and social predictors.

**METHODS:** Thissecondary analysis study utilizes the Enhancing Recovery in Coronary Heart Disease (ENRICHD) clinical trial data. From 1834 depressed patients in the ENRICHD study, there were 770 depressed post-MI patients who were treated for depression. In this study, TRD is defined as having a less than 50% reduction in Hamilton Depression (HAM-D) score from baseline and a HAM-D score of greater than 10 in six months after depression treatment began. Cox regression analysis was used to examine the independent contributions of TRD to mortality after controlling for the biological and social predictors.

**RESULTS:** Treatment Resistant Depression occurred in 13.4% (*n* = 103) of the 770 patients treated for depression. Patients with TRD were significantly younger in age (*P* = 0.04) (mean = 57.0 years, SD = 11.7) than those without TRD (mean = 59.2 years, SD = 12.0). There was a significantly higher percentage of females with TRD (57.3%) compared to females without TRD (47.4%) [*χ*2 (1) = 4.65, *P* = 0.031]. There were significantly more current smokers with TRD (44.7%) than without TRD (33.0%) [*χ*2(1) = 7.34, *P* = 0.007]. There were no significant differences in diabetes (*P* = 0.120), history of heart failure (*P* = 0.258), prior MI (*P* = 0.524), and prior stroke (*P* = 0.180) between patients with TRD and those without TRD. Mortality was 13% (*n* = 13) in patients with TRD and 7% (*n* = 49) in patients without TRD, with a mean follow-up of 29 mo (18 mo minimum and maximum of 4.5 years). TRD was a significant independent predictor of mortality (HR = 1.995; 95%CI: 1.011-3.938, *P* = 0.046) after controlling for age (HR = 1.036; 95%CI: 1.011-1.061, *P* = 0.004), diabetes (HR = 2.912; 95%CI: 1.638-5.180, *P* < 0.001), heart failure (HR = 2.736; 95%CI: 1.551-4.827, *P* = 0.001), and smoking (HR = 0.502; 95%CI: 0.228-1.105, *P* = 0.087).

**CONCLUSION:** The analysis of TRD in the ENRICHD study shows that the effective treatment of depression reduced mortality in depressed post-MI patients. It is important to monitor the effectiveness of depression treatment and change treatments if necessary to reduce depression and improve cardiac outcomes in depressed post-MI patients.

 **Key words:** Depression treatment; Post-myocardial infarction; Mortality; Anti-depressant; Cognitive behavioral therapy

**© The Author(s) 2015.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** Treatment resistant depression (TRD) was associated with increased mortality in post-myocardial infarction (MI) patients with depression. Conversely, effective treatment of depression with cognitive behavioral therapy with or without medication decreased mortality in post-MI patients who were depressed. Since TRD post-MI patients are at higher risk for mortality, closer follow-up and more aggressive treatment for depression and risk factor modification is needed to improve patient outcome. It is important to monitor the effectiveness of depression treatment and change treatments if necessary to reduce depression and improve cardiac outcomes in post-MI patients with depression.

Banankhah SK, Friedmann E, Thomas S. Effective treatment of depression improves post-myocardial infarction survival. *World J Cardiol* 2015; In press

**INTRODUCTION**

Depression predicts morbidity and mortality in patients after myocardial infarction (MI)[1-5]. Depression in post-MI patients is associated with increased mortality A meta-analysis of 29 studies with an average of 16 months follow-up and a total of 16889 patients revealed that post-MI depression is associated with more than doubling in odds of all cause mortality (OR, 2.25, 95%CI: 1.73-2.93; *P* < 0.001)[6]. Prevalence of depression is about 20% in patients with MI, compared to 5% in the general population[7,8]. Depression predicts a poorer prognosis and lower functional status in post-MI patients[4].

Treating depression in depressed post-MI patients should improve their long-term prognosis; however, in randomized clinical trials treating depression in depressed post-MI patients did not improve their survival[9-12].

Cognitive behavioral therapy, plus adjunctive sertraline treatment in the case of insufficient response, did not improve mortality or nonfatal re-infarction with a mean 29 mo follow-up in post-MI patients with depression and/or low perceived social support (LPSS) enrolled in the Enhancing Recovery in Coronary Heart Disease (ENRICHD) clinical trial[9]. There was no difference in event-free survival between the intervention and usual care groups (75.5% *vs* 74.7%). The intervention resulted in a temporary reduction in depression, which was present at 6 mo but disappeared by 30 mo after randomization[9]. Similarly, depression treatment did not improve cardiac event-free survival (treatment group 86.2% *vs* usual care group 87.3%) during the 18 mo of follow-up in the Myocardial Infarction and Depression-Intervention Trial (MIND-IT).[11] Antidepressant medication (sertraline) for depressed patients with heart disease (*n* = 369) resulted in a slight, but non-significant reduction in recurrent MI and death after an average of 30 mo of follow-up (RR = 0.77; 95%CI: 0.51-1.16) in the Sertraline Antidepressant Heart Attack Randomized Trial (SADHART) [10]. The recent 8-year follow-up of the MIND-IT trial that evaluated the effects of antidepressant treatment in depressed post-MI patients revealed that the treatment group’s mortality was not reduced when compared usual care group [12]. However, patients who actually received treatment for depression, regardless of group assignment, had an improved mortality (HR: 0.52, 95%CI: 0.28-0.97).

Secondary analyses of data from subgroups within clinical trials hint that the effectiveness of the treatment of depression might be a factor in whether treatment improves health outcomes. In an on-treatment secondary analysis of the 1834 depressed patients from the ENRICHD intervention and control groups showed significantly lower risk of recurrent MI and death in patients taking selective serotonin reuptake inhibitors (SSRIs) from both the usual care and treatment group. During an average of 29 mo of follow-up, 26% of patients who did not receive antidepressants died or had a recurrent MI *vs* 21.5% of patients on antidepressant therapy. Use of SSRIs was associated with significant reduction in risk of death or nonfatal MI (HR = 0.72; 95%CI: 0.44-1.22) and of all-cause mortality (HR = 0.73; 95%CI: 0.34-1.38)[13].

In patients with at least 1 prior episode of major depression in the ENRICD intervention group whose depression did not improve over the first 6 mo had higher late mortality (unimproved 21.2% *vs* improved 10.4%) and were more likely to be taking antidepressant medication and have a higher body mass index at enrollment than patients whose depression symptoms improved. In the usual care arm of ENRICHD, improvement in depression was not related to mortality[2].

In a 7-year follow-up analysis of SADHART, patients whose major depression did not respond to medication experienced 2.39 times as much mortality (28.4%) as those whose depression was treated effectively (15.6%)[14].

The ENRICHD study did not find that randomized treatment of depression in depressed post-MI patients decreased mortality or morbidity. Even with extensive effort to treat their depression, many patients in the intervention arm did not improve their depression symptoms after 6 months of treatment. Instead, they seem to have a treatment refractory depression that was resistance to current available therapy. This finding and other subsequent analysis of ENRICHD studies left health professionals without clear direction for the treatment of depression in post-MI patients.

Clinical studies show that not all depressed patients respond adequately to treatment. Fava *et al*[15] meta-analysis of 36 clinical trials demonstrated that about 50% of depressed patients have an adequate response to antidepressant therapy, 15% had partial response, and 20%-35% did not respond to depression treatment. Patients who do not respond adequately labeled as treatment resistant. Depression was considered treatment resistant when at least 2 trials of different antidepressant therapy with adequate dose/duration/compliance failed to produce a significant clinical improvement in depression symptoms[16].

Patients with treatment resistant depression (TRD) in previous studies may have masked the effect of reducing depression on improvement of survival of depressed post-MI patients. In a cohort study of 4037 depression post-MI patients 12.1% of the patients had treatment-resistant depression and they were 1.71 times as likely to die than treated patients[17].

The current study focuses on TRD and compares survival of patients with TRD to survival of patients who responded to treatment of depression.

**MATERIALS AND METHODS**

***Research design***

This secondary data analysis uses longitudinal data from the ENRICHD randomized clinical trial. The limited use de-identified data set was obtained from NHLBI after University of Maryland full IRB review.

***Data source***

ENRICHD was the first randomized multi-center study to examine the effect of psychosocial intervention on survival in patients who were depressed and/or had low perceived social support (LSSP) after an MI. Sponsored by National Heart, Lung, and Blood Institute (NHLBI). Recruitment started in October 1996 and ended in October 1999. Patients were enrolled in the ENRICHD study within 28 d of an acute MI.

All patients with an acute MI admitted to 1 of the 73 participating hospitals were screened for acute MI eligibility including MI documented by cardiac enzymes and by chest pain with typical ST-T changes or new Q waves. Complete ENRICHD inclusion and exclusion criteria are published elsewhere[9]. After informed consent was obtained, patients were screened for depression and/or LPSS. If either depression or LPSS was present, patients were randomly assigned to the intervention or usual care arm. Participants had follow-up examinations at 6 and 18 mo and annually thereafter. The primary end-point of the study was the occurrence of re-infarction or all cause mortality[9].

***ENRICHD intervention***

Cognitive Behavioral Therapy (CBT) was utilized as the standard of the ENRICHD intervention[18]. Intervention group patients with scores higher than 24 on the Hamilton Rating Scale for Depression (HAM-D) or who had < 50% reduction in BDI score after 5 wk were referred to study psychiatrists for pharmacotherapy consideration. If there were no contraindications, sertraline hydrochloride was used as the drug of choice. The maximum CBT duration was 6 mo[9].

Patients in the usual care arm of the study received only the care provided by their primary care providers, which was standard medical care for post-MI patients. Patients in both groups received health education regarding cardiovascular disease and its management and both groups received standard medical treatment as practiced in that institution.

***ENRICHD measures***

Baseline assessment in ENRICHD included demographics, cardiovascular health history, risk factors, current medications, detailed medical record documentation of the course of treatment for the acute MI, an ECG, the Depression Interview and Structured Hamilton (DISH), Beck Depression Inventory (BDI), and ENRICHD Social Support Inventory (ESSI).

The DISH is a semi-structured interview developed for ENRICHD trial and was used for screening and diagnosing depression[19] using principles and criteria from the *Diagnostic and Statistical Manual of Mental Disorders*, Fourth Edition (DSM-IV)[20]. The DISH incorporated material from the 17-item version of the Hamilton Rating Scale for Depression (HAM-D)[21], the Structured Interview Guide for the Hamilton Depression Scale (SIGH-D)[22], the Diagnostic Interview Schedule (DIS)[23], and the modified versions of the DIS[24]. The DISH depression severity score was based on the 17-item HAM-D. The first 9 items on HAMD-D are 5 point Likert format ranging from 0 (absent) to 4 (severe). The last 8 items are 3 point Likert format ranging from 0(absent) to 2 (clearly present). The possible score ranges from 0 to 50. Scores of > 10 indicates the presence of depression symptoms. Higher total scores indicate more depression symptom severity. The concurrent validity of DISH was evaluated using the Pearson correlation coefficient between 17-item HAM-D embedded in the DISH and BDI scores that resulted in a correlation of 0.76 (*P* < 0.001)[19]. The DISH was administered at the screening phase of the ENRICHD study and at 6 mo follow-up.

 The BDI[22] was used in the ENRICHD study to evaluate baseline depression status and assess progress during treatment and follow-up. The BDI is the most widely use depression instrument in clinical and research settings. The BDI is considered 1 of the best methods to assess presence and severity of depression. It is easy to use and only takes 5 min to complete by the patient or provider. The BDI is a 21-item inventory, and each item is rated on a 0 to 3 scale with a total score ranging from 0 to 64. BDI scores > 10 indicate depression, scores of 10-15 mild depression, 16-23 moderate depression, and 24-64 severe depression. Concurrent validity of BDI was established by comparing BID to HAM-D that positively correlated (r = 0.71, *n* = 87). This indicates an acceptable concurrent validity of BDI. The BDI was administered to all participants at baseline, 6, 12, 18 mo and annually thereafter.

The ESSI was used in the ENRICHD study to assess perceived social support at baseline and during treatment and follow-up. It was developed for ENRICHD study to measure functional social support. The ESSI was used as a screening tool to determine patients’ eligibility for ENRICHD based on low social support, and to assess changes in patients’ social support following treatment. The ESSI is a 7-item inventory, and item 1 to 6 is rated on a 1 to 5 scale, which indicates none to all respectively. Item 7 is not rated on numeric scale. The total score ranges from 6 to 30 with lower scores indicating lower perceived social support. A score of < 3 on 2 or more items and a total score of < 18, or a score of 2 on 2 items without regard to total score indicated low perceived social support which was the criteria for inclusion in ENRICHD trial[26]. In this study, 3 variables derived from ESSI instrument that were live alone, perceived social support, and social isolation. Live alone was the seventh question on the ESSI questionnaire (Do you live alone?) that was separated and transferred into the study dataset. Perceived social support was the total score on the ESSI and social isolation was dichotomous value based on scoring the ESSI. Social isolation was defined as meeting the ENRICHD criteria for LPSS. The reliability of ESSI was estimated by using test-retest reliability that showed no significant differences in mean scores administered 1 mo apart (*P* = 0.98). The internal reliability was measured with the use of Cronbach’s alpha that revealed an alpha of 0.88, which indicates a high internal consistency. The intra-class correlation coefficient was 0.94, reflecting excellent reproducibility[26]. The ESSI was administered to all participants at baseline, 6, 12, 18 mo and annually thereafter.

***Sample***

The study sample consists of the depressed patients in either arm of ENRICHD who received treatment for depression and completed the DISH at 6 mo. Treatment was defined as any combination of CBT and/or antidepressant medication. TRD was defined as < 50% improvement of 6-mo HAM-D score from baseline in patients with 6-mo HAM-D > 10. The outcome variable in this study was all cause mortality. All deaths were documented and verified by the ENRICHD investigators.

***Statistical methods***

**Data analysis:** Normality of distributions of continuous variables was examined; no variables had extreme values that needed transformation[27]. Missing data was < 5% thus there was not a need to examine patterns of missing data[27]. All inferential tests conducted at the 0.05 level of significance. Statistical procedures were performed using SPSS version 20.0 software.

Cox Regression Analyses was used to examine the hypothesis. The proportional hazards assumption of Cox regression was confirmed. The contribution of each biological (age, female gender, minority status, and presence of diabetes, history of heart failure, hypertension, prior MI, prior stroke, and current smoker), social (lives alone, perceived social support, social isolation), and psychological (baseline depression symptoms and TRD) predictor to mortality was initially examined in individual Cox regression analyses. Age was centered on 34 years, the lowest age in the study for ease of interpretation. The reference group (0) for dichotomous predictors was the un-named category. A combined model was constructed with biological and psychological, and social factors that predicted mortality at *P* < 0.20 in the individual analyses. Based on prior research showing differences between men and women in reporting depression[28,29], the interaction of TRD and female gender was added to the model. Similarly, based on prior research showing differences between minorities and non-minorities in reporting depression[30] the interaction of TRD and minorities status was added to the model. Neither of the interaction were significant predictors of mortality so they were not included in the final parsimonious Cox regression combined model. Biostatistician reviewed the statistical methods of this study.

**Sample description:** A total of 770 ENRICHD participants were depressed at the study entry and received depression treatment (Table 1). These participants received cognitive behavior treatment (CBT) (*n* = 469, 60.9%), or antidepressant medication (*n* = 85, 11%), or both (*n* = 216, 28.1%). The sample included 365 (47%) women and 239 (31%) minority participants. Ages ranged from 34 to 85 with a mean of 59 (SD = 12) years. Treatment resistant depression was present in 103 (13.4%) of the patients who were treated for depression.

***Biostatistics***

The statistical methods of this study were reviewed by Erika Friedmann from University of Maryland.

**RESULTS**

Baseline characteristics of patients with and without TRD were compared (Table 1). Patients with TRD were significantly younger (*P* = 0.04), more likely to be female (*P* = 0.031), be hypertensive (*P* = 0.033), and have lower perceived social support (*P* = 0.006) than those without TRD. Major depression was significantly more common (*P* < 0.001) and baseline depression symptom severity assessed with the BDI was significantly worse (*P* < 0.001) among patients who experienced TRD.

Of the 770 participants, there were 62 (8%) deaths with an average follow-up of 29 mo. All cause mortality tended to be higher in the patients with TRD (13/103: 13%) than those whose depression responded to treatment (49/667: 7%) (X2= 3.35, *P* = 0.05).

In univariate Cox regression analysis (Table 2), age (*P* < 0.001), female gender (*P* = 0.005), diabetes (*P* < 0.001), history of heart failure (*P* < 0.001), hypertension (*P* = 0.002), prior MI (*P* < 0.001), prior stroke (*P* < 0.001), current smoker (*P* = 0.002) and live alone (*P* = 0.032) were significant predictors of mortality. Minority status (*P* = 0.943), perceived social support (*P* = 0.279), social isolation (p = 0.446), and baseline depression symptoms (*P* = 0.978) did not predict mortality.

In the combined simultaneous Cox regression model, TRD (*P* = 0.046), age (*P* = 0.004), diabetes (*P* < 0.001), and history of heart failure (*P* = 0.001) were significant independent predictors of mortality; current smoker tended to predict mortality (*P* = 0.087) (Table 3).

When the interaction between female gender and TRD and minority status and TRD were each added to the model, the interactions were not significant (*P* = 0.467, *P* =0.87, respectively). Neither interaction was added to the final model. In the final model TRD contributed significantly to mortality (*P* = 0.046) after controlling for age, diabetes, heart failure, and currently smoking. Patients with TRD had approximately double the risk of all cause mortality compared with patients without TRD (95%CI: 1.011-3.938). Other significant independent predictors of mortality were age, diabetes and heart failure.

This study showed a significant improvement in survival in depressed post-MI patients whose depression was effectively treated (Figure 1). Among treated depressed post-MI patients, TRD was a significant independent predictor of mortality after controlling for biological and social factors.

**DISCUSSION**

Not all depressed patients respond adequately to treatment, and their depression does not improve significantly with current depression treatments. These depressed patients are treatment resistant[13]. Recent studies do not show improved mortality of acute myocardial infarction patients after treatment for depression[8-12].One explanation of this may be that previous studies of post-MI patients included a subgroup of patients with TRD who may have impacted the results. The presence of the TRD sub-group may cause a failure in the study’s ability to show improved survival in the intervention group.

The purpose of this study was to examine the differences in mortality between patients with TRD and those without TRD. The significant predictors for mortality among depressed post-MI patients whose depression was treated were; age, diabetes, and history of heart failure. The presence of TRD significantly predicted mortality after controlling for these other factors (HR = 1.995). TRD was associated with an increased risk of mortality when compared to non-TRD patients. This finding is consistence with the 7-year follow-up analysis of the Sertraline Antidepressant Heart Attack Randomized Trial (SADHART) [10]. Initial findings of SADHEART revealed a non-significant reduction in re-current MI and death (RR = 0.77; 95%CI: 0.51-1.16) in treated depressed individuals. At that time, they did not examine the difference between survival in those individuals who responded and not respondent to depression treatment. Subsequently, the 7-year follow-up analysis of the SADHART trial found that patients with major depression who responded to treatment with sertraline had a reduction in mortality versus non-responders (15.6% *vs* 28.4%; HR, 2.39) [14]. The current study extends this finding from post MI patients with major depression to less psychologically distressed patients, namely post MI patients with dysthymia through major depression. Further the current study began treatment with cognitive behavioral therapy and added medication if depression was not responsive. This study is also consistent with Scherre *et al*’s[17] cohort study’s finding that post-MI patients with TRD had increased mortality. The criteria for TRD in that study were that: the patient received (1) electroconvulsive therapy, (2) a monoamine oxidease inhibitor, or (3) two or more antidepressant at the same time. In contrast, the current study uses depression measurement tools to identify post-MI patients with TRD.

This re-analysis of the ENRICHD study data clearly shows that successful treatment of depression decreases mortality in post-MI patients. It also demonstrates that current depression treatments are not effective in treating all depressed post-MI patients. According to this study, over 13% of treated patients still suffered from depression at the end the treatment. This is consistent with the Scherre study, which showed 12.1% of post-MI patients experienced TRD. Perhaps a treatment that is more effective in alleviating depression would improve survival in post-MI patients. Until more effective treatments are developed, closer follow-up of depression symptoms, aggressive treatment of depression, actively treating other modifiable risk factors, and modifying risky health behaviors may lead to a better survival in post-MI patients with TRD.

***Strengths and limitations***

This study was a secondary data analysis of an existing trial. This places limitation to this study regarding control over the variable definition, measurement, data collection and other crucial aspects of the study design. With this study, we were not able to establish causality of the contributions of TRD for mortality. The study findings were only able to provide evidence of the associations between the variables. Despite the limitations of this study, the strengths outweigh the limitations of the study. Using a large existing database, this study has the advantage of providing a representative sample. Women and minorities were well represented in the ENRICHD data. ENRICHD included detailed questionnaire development, data collection procedures, data management, and quality control measures. The use of ENRICHD dataset provided an opportunity to use high quality dataset without the high cost and effort of obtaining this type and amount of data.

***Implications for practice and future research***

The analysis of TRD in ENRICHD shows that treatment of depression in the ENRICHD sample was effective in reducing mortality in those whose depression was effectively reduced by cognitive behavioral therapy and/or anti-depressant medication. By separating out those who were depressed and whose treatment was effective it was possible to evaluate the contribution of effective treatment of depression to mortality in post-MI patients. The findings of this study provided evidence that depressed patients with TRD have more than double the risk of mortality when compared with patients whose depression is effectively treated. This sub-group of depressed patients with TRD did not improve their depression symptoms with their current depression treatment. Closer follow-ups of depression symptoms, aggressive treatment of depression, aggressively treating other modifiable risk factors, and modifying risky health behaviors may lead to a better chance of survival in TRD post-MI patients.

As shown in this current study, depression is a risk factor for mortality among TRD post-MI patients. Yet the question remains how to best treat it. Future research is needed to address the development of effective treatment for depression. Both ENRICHD and SADHART trials reported small effect size using current depression interventions, this suggest a need to increase efficacy of current interventions for depressed post-MI patients. The results of the present study accentuate the need for future research for drug development and effective interventions to alleviate depression symptoms in order to improve cardiac outcomes.

The potential mechanisms linking depression and impaired cardiovascular prognosis are still poorly understood and remain an area that is in need of more research. Future studies are needed to give insight and provide evidence that will direct us toward a future in which we, health providers, are able to help and improve survival in post-MI patients who have TRD.

This study provided evidence that TRD is associated with increased mortality in post-MI patients who are depressed. Conversely, effective treatment of depression with cognitive behavioral therapy without or with medication decreased mortality in post-MI patients who were depressed. Since, TRD post-MI patients are at higher risk for mortality, closer follow-up and more aggressive treatment for depression and risk factor modification is needed to improve patients' outcomes. This may lead to an integrated treatment strategy that may decrease risk of mortality in post-MI patients. It is important to monitor the effectiveness of depression treatment and change treatments if necessary to reduce depression and improve cardiac outcomes in post-MI patients who are depressed.

**ACKNOWLEDGEMENTS**

This manuscript was prepared using the Enhancing Recovery in Coronary Heart Disease (ENRICHD) limited access dataset obtained from the NHLBI Biologic Specimen and Data Repository Information Coordinating Center and does not necessarily reflect the opinions or views of the ENRICHD Study or the NHLBI. The authors thank the investigators, coordinators, staff, and patients of the ENRICHD Study.

**COMMENTS**

***Background***

Depression increases mortality after myocardial infarction (MI). Clinical trials have not demonstrated a reduction in mortality with depression treatment. Depression treatment is not effective in a substantial proportion of the depressed patients. The presence of treatment resistant depression (TRD) may explain why previous clinical trials did not demonstrate decreased mortality when depression was treated.

***Research frontiers***

Recent clinical studies show that not all depressed patients respond adequately to treatment, and their depression does not improve significantly with current depression treatments. These patients have TRD. Presently, there is no study that shows improved outcome of depressed patients with acute MI by treating depression. This can be explained by the presence of TRD in some post-MI patients, which would impact the results of the study. The presence of TRD may cause a failure in the study’s ability to show improved survival in the intervention group.

***Innovations and breakthroughs***

This study considers the presence of TRD in depressed post-MI patients and its influence on prior analysis. Treatment resistant depression is a possible explanation for why previous clinical trials did not demonstrate decreased mortality when depression was treated. The result of this study reveals that treatment resistant depression significantly predicts mortality after controlling for biological and social factors. Among depression treated post MI patients, TRD was associated with an increased risk of mortality when compared to non-TRD patients. Depressed patients with TRD have double the risk of mortality when compared with patients whose depression is effectively treated.

***Applications***

This study provides new evidence that depressed patients with TRD did not improve their mortality with current depression treatment, and they are in desperate need for more efficacious depression treatment. Closer follow-ups of depression symptoms, aggressive treatment of other modifiable risk factors, and modifying risky health behaviors may lead to a better chance of survival in depressed post-MI patients. This knowledge may assist primary care providers regarding clinical decision making that provides a better treatment options for patients.

***Terminology***

Treatment resistant depression (TRD) is a term describing patients with depression symptoms that do not improve after treatment is completed. In other words, the total HAM-D score does not decrease more than 50% from baseline with a total HAM-D score above 10 after completing depression treatment.

***Peer-review***

Authors showed that effective treatment of depression improved survival of patients after AMI. This paper is well described, and includes important clinical findings.

**REFERENCES**

1 **Huffman JC**, Smith FA, Blais MA, Taylor AM, Januzzi JL, Fricchione GL. Pre-existing major depression predicts in-hospital cardiac complications after acute myocardial infarction. *Psychosomatics* 2008; **49**: 309-316 [PMID: 18621936 DOI: 10.1176/appi.psy.49.4.309]

2 **Carney RM**, Blumenthal JA, Freedland KE, Youngblood M, Veith RC, Burg MM, Cornell C, Saab PG, Kaufmann PG, Czajkowski SM, Jaffe AS. Depression and late mortality after myocardial infarction in the Enhancing Recovery in Coronary Heart Disease (ENRICHD) study. *Psychosom Med* 2004; **66**: 466-474 [PMID: 15272090 DOI: 10.1097/01.psy.0000133362.75075.a6]

3 **Lane D**, Carroll D, Lip GY. Anxiety, depression, and prognosis after myocardial infarction: is there a causal association? *J Am Coll Cardiol* 2003; **42**: 1808-1810 [PMID: 14642692 DOI: 10.1016/j.jacc.2003.08.018]

4 **Bush DE**, Ziegelstein RC, Tayback M, Richter D, Stevens S, Zahalsky H, Fauerbach JA. Even minimal symptoms of depression increase mortality risk after acute myocardial infarction. *Am J Cardiol* 2001; **88**: 337-341 [PMID: 11545750 DOI: 10.1016/S0002-9149(01)01675-7]

5 **Frasure-Smith N**, Lespérance F, Talajic M. Depression following myocardial infarction. Impact on 6-month survival. *JAMA* 1993; **270**: 1819-1825 [PMID: 8411525 DOI: 10.1001/jama.1993.03510150053029]

6 **Meijer A**, Conradi HJ, Bos EH, Thombs BD, van Melle JP, de Jonge P. Prognostic association of depression following myocardial infarction with mortality and cardiovascular events: a meta-analysis of 25 years of research. *Gen Hosp Psychiatry* 2011; **33**: 203-216 [PMID: 21601716 DOI: 10.1016/j.genhosppsych.2011.02.007]

7 **Thombs BD**, Bass EB, Ford DE, Stewart KJ, Tsilidis KK, Patel U, Fauerbach JA, Bush DE, Ziegelstein RC. Prevalence of depression in survivors of acute myocardial infarction. *J Gen Intern Med* 2006; **21**: 30-38 [PMID: 16423120 DOI: 10.1111/j.1525-1497.2005.00269.x]

8 **Rudisch B**, Nemeroff CB. Epidemiology of comorbid coronary artery disease and depression. *Biol Psychiatry* 2003; **54**: 227-240 [PMID: 12893099 DOI: 10.1016/S0006-3223(03)00587-0]

9 **Berkman LF**, Blumenthal J, Burg M, Carney RM, Catellier D, Cowan MJ, Czajkowski SM, DeBusk R, Hosking J, Jaffe A, Kaufmann PG, Mitchell P, Norman J, Powell LH, Raczynski JM, Schneiderman N. Effects of treating depression and low perceived social support on clinical events after myocardial infarction: the Enhancing Recovery in Coronary Heart Disease Patients (ENRICHD) Randomized Trial. *JAMA* 2003; **289**: 3106-3116 [PMID: 12813116 DOI: 10.1001/jama.289.23.3106]

10 **Glassman AH**, O'Connor CM, Califf RM, Swedberg K, Schwartz P, Bigger JT, Krishnan KR, van Zyl LT, Swenson JR, Finkel MS, Landau C, Shapiro PA, Pepine CJ, Mardekian J, Harrison WM, Barton D, Mclvor M. Sertraline treatment of major depression in patients with acute MI or unstable angina. *JAMA* 2002; **288**: 701-709 [PMID: 12169073 DOI: 10.1001/jama.288.6.701]

11 **van Melle JP**, de Jonge P, Honig A, Schene AH, Kuyper AM, Crijns HJ, Schins A, Tulner D, van den Berg MP, Ormel J. Effects of antidepressant treatment following myocardial infarction. *Br J Psychiatry* 2007; **190**: 460-466 [PMID: 17541103 DOI: 10.1192/bjp.bp.106.028647]

12 **Zuidersma M**, Conradi HJ, van Melle JP, Ormel J, de Jonge P. Depression treatment after myocardial infarction and long-term risk of subsequent cardiovascular events and mortality: a randomized controlled trial. *J Psychosom Res* 2013; **74**: 25-30 [PMID: 23272985 DOI: 10.1016/j.jpsychores.2012.08.015]

13 **Taylor CB**, Youngblood ME, Catellier D, Veith RC, Carney RM, Burg MM, Kaufmann PG, Shuster J, Mellman T, Blumenthal JA, Krishnan R, Jaffe AS. Effects of antidepressant medication on morbidity and mortality in depressed patients after myocardial infarction. *Arch Gen Psychiatry* 2005; **62**: 792-798 [PMID: 15997021 DOI: 10.1001/archpsyc.62.7.792]

14 **Glassman AH**, Bigger JT, Gaffney M. Psychiatric characteristics associated with long-term mortality among 361 patients having an acute coronary syndrome and major depression: seven-year follow-up of SADHART participants. *Arch Gen Psychiatry* 2009; **66**: 1022-1029 [PMID: 19736359 DOI: 10.1001/archgenpsychiatry.2009.121]

15 **Fava M**, Davidson KG. Definition and epidemiology of treatment-resistant depression. *Psychiatr Clin North Am* 1996; **19**: 179-200 [PMID: 8827185 DOI: 10.1016/S0193-953X(05)70283-5]

16 **Berlim MT**, Turecki G. Definition, assessment, and staging of treatment-resistant refractory major depression: a review of current concepts and methods. *Can J Psychiatry* 2007; **52**: 46-54 [PMID: 17444078]

17 **Scherrer JF**, Chrusciel T, Garfield LD, Freedland KE, Carney RM, Hauptman PJ, Bucholz KK, Owen R, Lustman PJ. Treatment-resistant and insufficiently treated depression and all-cause mortality following myocardial infarction. *Br J Psychiatry* 2012; **200**: 137-142 [PMID: 22241930 DOI: 10.1192/bjp.bp.111.096479]

18 **Beck AT,** Steer RA, Brown GK. Manual for the Beck Depression Inventory–II. San Antonio, TX: Psychological Corporation, 1996

19 **Freedland KE**, Skala JA, Carney RM, Raczynski JM, Taylor CB, Mendes de Leon CF, Ironson G, Youngblood ME, Krishnan KR, Veith RC. The Depression Interview and Structured Hamilton (DISH): rationale, development, characteristics, and clinical validity. *Psychosom Med* 2002; **64**: 897-905 [PMID: 12461195 DOI: 10.1097/01.psy.0000028826.64279.29]

20 **American Psychiatric Association.** Diagnostic and statistical manual of mental disorder, 4th edition. Washington, D.C.: American Psychiatric Association, 1994

21 **Hamilton M**. A rating scale for depression. *J Neurol Neurosurg Psychiatry* 1960; **23**: 56-62 [PMID: 14399272 DOI: 10.1136/jnnp.23.1.56]

22 **Williams JB**. A structured interview guide for the Hamilton Depression Rating Scale. *Arch Gen Psychiatry* 1988; **45**: 742-747 [PMID: 3395203 DOI: 10.1001/archpsyc.1988.01800320058007]

23 **Robins LN**, Helzer JE, Croughan J, Ratcliff KS. National Institute of Mental Health Diagnostic Interview Schedule. Its history, characteristics, and validity. *Arch Gen Psychiatry* 1981; **38**: 381-389 [PMID: 6260053 DOI: 10.1001/archpsyc.1981.01780290015001]

24 **Carney RM**, Rich MW, Freedland KE, Saini J, teVelde A, Simeone C, Clark K. Major depressive disorder predicts cardiac events in patients with coronary artery disease. *Psychosom Med* 1988; **50**: 627-633 [PMID: 2976950 DOI: 10.1097/00006842-198811000-00009]

25 **Beck AT**, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. *Arch Gen Psychiatry* 1961; **4**: 561-571 [PMID: 13688369 DOI: 10.1001/archpsyc.1961.01710120031004]

26 **Vaglio J**, Conard M, Poston WS, O'Keefe J, Haddock CK, House J, Spertus JA. Testing the performance of the ENRICHD Social Support Instrument in cardiac patients. *Health Qual Life Outcomes* 2004; **2**: 24 [PMID: 15142277 DOI: 10.1186/1477-7525-2-24]

27 **Tabachnick BG,** Fidell LS. Using Multivariate Statistic. (Fifth ed.) New York: Pearson Education, Inc, 2007

28 **Kessler RC**, McGonagle KA, Swartz M, Blazer DG, Nelson CB. Sex and depression in the National Comorbidity Survey. I: Lifetime prevalence, chronicity and recurrence. *J Affect Disord* 1993; **29**: 85-96 [PMID: 8300981 DOI: 10.1016/0165-0327(93)90026-G]

29 **Nolen-Hoeksema S.** Gender differences in depression. *CDPS* 2001; **10:** 173-176 [DOI: 10.1111/1467-8721.00142]

30 **Ghafoori B**, Barragan B, Tohidian N, Palinkas L. Racial and ethnic differences in symptom severity of PTSD, GAD, and depression in trauma-exposed, urban, treatment-seeking adults. *J Trauma Stress* 2012; **25**: 106-110 [PMID: 22354513 DOI: 10.1002/jts.21663]

**P- Reviewer:** Chang ST, Kounis NG, Kurisu S, Tampi RR

 **S- Editor:** Song XX **L- Editor: E- Editor:**



**Figure 1 Hazard function for treatment resistant depression and non- treatment resistant depression participants to mortality after myocardial infarction.**

**Table 1 Summary of demographic biological, social, and psychological characteristics of depressed post-myocardial infarction patients treated for depression and comparison of those with treatment resistant and non treatment resistant depression (*n* = 770) *n* (%)**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Characteristics | Treated Depressed Post-MI1 | TRD*n* = 1031 | Non TRD*n* = 6671 |  |
| Demographics and biological characteristics |  |  |  |  |
| Age, mean (SD), years | 59.2 (12.0) | 57.0 (11.7) | 59.5 (12.0) | t = -2.07, *P* = 0.04 |
| Gender, female | 365 (47.4) | 59 (57.3) | 306 (45.9) | X2 (1) = 4.65, *P* = 0.031 |
| Ethnicity, minority | 239 (31.0) | 32 (31.1) | 207 (31.0) | X2 (1) = 0.0, *P* = 0.995 |
| Education: |  |  |  | X2 (2) = 3.76, *P* = 0.153 |
|  Basic or no HS degree | 187 (24.3) | 25 (24.3) | 162 (24.3) |  |
|  HS without college degree | 419 (54.4) | 64 (62.1) | 355 (53.2) |  |
|  Advanced education | 146 (19.0) | 13 (12.6) | 133 (19.9) |  |
| Body mass index, mean (SD) | 29.2 (6.1) | 29.7 (6.3) | 29.2 (6.1) | t = 0.77, *P* = 0.444 |
| Diabetes | 264(34.3) | 42 (40.8) | 222 (33.3) | X2 (1) = 2.41, *P* = 0.120 |
| History of heart failure | 101 (13.1) | 17 (16.5) | 84 (12.6) | X2 (1) = 1.28, *P* = 0.258 |
| Hypertension | 458 (59.5) | 70 (68.0) | 388 (58.2) | X2 (1) = 4.56, *P* = 0.033 |
| Prior MI | 187 (24.3) | 22 (21.4) | 165(24.7) | X2 (1) = 0.41, *P* = 0.524 |
| Prior stroke | 70 (9.1) | 13 (12.9) | 57 (8.7) | X2 (1) = 1.80, *P* = 0.180 |
| Current smoker | 254 (33.0) | 46 (44.7) | 208 (31.2) | X2 (1) = 7.34, *P* = 0.007 |
| Social characteristics |  |  |  |  |
| Live alone  | 322 (41.8) | 46(44.7) | 276 (41.4) | X2 (1) = 0.32, *P* = 0.570 |
| Social support | 356 (46.2) | 54(52.4) | 302(45.3) | X2 (1) = 1.84, *P* = 0.176 |
| Psychological characteristics |  |  |  |  |
| Depression  |  |  |  | X2 (2) = 16.7, *P* > 0.001 |
|  Major depression | 398 (51.7) | 69 (67.0) | 329 (49.3) |  |
|  Minor depression  | 348 (45.2) | 28 (27.2) | 320(48.0) |  |
|  Dysthymia | 24 (3.1) | 6 (5.8) | 18 (2.7) |  |
| Psychosocial measures |  |  |  |  |
| Baseline Depression Symptom Severity (BDI), mean (SD) | 17.7 (7.8) | 22.4 (9.3) | 17.0 (7.4) | t = 6.62, *P* < 0.001 |
| Baseline Perceived Social Support (ESSI), mean (SD) | 24.5(6.4) | 22.9 (7.0) | 24.7 (6.3) | t = -2.74, *P* = 0.006 |
| Baseline Depression Symptom (HAM-D), mean (SD) | 17.9 (6.3) | 20.9 (6.5) | 17.4 (6.1) | t = 5.07, *P* < 0.001 |

1Except where mean (SD) is noted. BDI: Beck Depression Inventory; ESSI: ENRICHD Social Support Inventory; HAM-D: Hamilton Depression Rating Scale; HS: High school TRD: Treatment resistant depression; MI: Myocardial infarction.

**Table 2 Results of separate Cox regression analyses to examine the contributions of each biological, social and psychological predictor to mortality among treated post- myocardial infarction patients with depression (*n* = 770)**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | B | SE | Wald | Sig. | HR | 95%CI |
| Biological factors |  |  |  |  |  |  |
|  | Age1 | 0.048 | 0.011 | 19.205 | <0.001 | 1.050 | 1.027-1.073 |
|  | Female gender | 0.741 | 0.266 | 7.791 | 0.005 | 2.098 | 1.247-3.531 |
|  | Minority status | 0.020 | 0.272 | 0.005 | 0.943 | 1.020 | 0.599-1.737 |
|  | Diabetes | 1.448 | 0.272 | 28.401 | <0.001 | 4.255 | 2.498-7.247 |
|  | Heart failure | 1.495 | 0.275 | 29.507 | <0.001 | 4.461 | 2.601-7.652 |
|  | Hypertension | 1.002 | 0.322 | 9.675 | 0.002 | 2.723 | 1.449-5.120 |
|  | Prior MI | 0.961 | 0.261 | 13.533 | <0.001 | 2.616 | 1.567-4.365 |
|  | Prior stroke | 1.165 | 0.306 | 14.496 | <0.001 | 3.207 | 1.760-5.843 |
|  | Current smoker | -1.128 | 0.361 | 9.781 | 0.002 |  0.324 | 0.160-.656 |
| Social factors |  |  |  |  |  |  |
|  | Live alone | 0.552 | 0.258 | 4.591 | 0.032 | 1.737 | 1.048-2.880 |
|  | Perceived social support | -0.046 | 0.028 | 2.768 | 0.096 | 0.955 | 0.904-1.008 |
|  | Social isolation | -0.197 | 0.258 | 0.582 | 0.446 | 0.822 | 0.496-1.361 |
| Psychological factor |  |  |  |  |  |  |
|  | Baseline depression symptom severity | <0.001 | 0.016 | 0.001 | 0.978 | 1.000 | 0.968-1.032 |
|  | Treatment resistant depression  | 0.534 | 0.312 | 2.927 | 0.087 | 1.705 | 0.925-3.143 |

1Age centered on the lowest age of 34 yr. For dichotomous variables reference group is the absence of the named predictor. MI: Myocardial infarction.

**Table 3 Final model: Results of Cox regression analysis to examine the independent contributions of biological, social, and psychological predictors and treatment resistant depression to all cause mortality among post-myocardial infarction patients treated for depression (*n* = 770)**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
|  |  | B | SE | Wald | Sig. | HR |  95% CI  |
| Biological factors |  |  |  |  |   |
|  | Age1 | 0.035 | 0.012 | 8.280 | 0.004 | 1.036 | 1.011-1.061 |
|  | Diabetes | 1.069 | 0.294 | 13.243 | 0.000 | 2.912 | 1.638-5.180 |
|  | Heart failure | 1.007 | 0.290 | 12.089 | 0.001 | 2.736 | 1.551-4.827 |
|  | Current smoker | -0.690 | 0.403 | 2.932 | 0.087 | 0.502 | 0.228-1.105 |
| Social factors |  |  |  |  |  |
|  | None |  |  |  |  |  |  |
| Psychological factor |  |  |  |  |  |
|  | Treatment resistant depression | 0.691 | 0.347 | 3.967 | 0.046 | 1.995 | 1.011-3.938 |

1Age centered on the lowest age of 34 yr. For dichotomous variables, reference group is the absence of the named predictor.